MASI Q1 Earnings Call: Revenue Tops Expectations, Focus Shifts to Healthcare Core Amid Tariff Headwinds

Medical tech company Masimo (NASDAQ: MASI) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $372 million. The company expects the full year’s revenue to be around $1.52 billion, close to analysts’ estimates. Its non-GAAP profit of $1.36 per share was 12.6% above analysts’ consensus estimates.

Is now the time to buy MASI? Find out in our full research report (it’s free).

StockStory’s Take

Masimo’s first quarter results were driven by double-digit growth in core healthcare sales, margin expansion, and operational efficiencies. CEO Katie Szyman attributed performance to strong demand for patient monitoring products, a successful large contract renewal, and improved cost controls. She also cited early progress in her commercial strategy and highlighted the company’s commitment to innovation as foundational for future growth.

Looking ahead, management’s guidance reflects the impact of new tariffs and continued investments in commercial and R&D initiatives. CFO Micah Young described the tariff environment as fluid, noting that mitigation plans are in progress but difficult to quantify for the full year. The company’s outlook is further shaped by the sale of its consumer audio business, with proceeds expected to support share repurchases. Szyman acknowledged ongoing uncertainty from tariffs and emphasized Masimo’s focus on operational execution and margin discipline.

Key Insights from Management’s Remarks

Masimo’s management identified several drivers behind Q1 performance and upcoming changes to its business focus. The sale of the consumer audio division and a renewed emphasis on healthcare technology are central to its evolving strategy.

• Divestiture of Sound United: Masimo entered an agreement to sell its consumer audio business, Sound United, allowing the company to concentrate resources on its healthcare segment. Management stated that the sale will help sharpen the company’s focus on patient monitoring and hospital solutions.
• Operational margin gains: Operating margin improvement was attributed to last year’s cost optimization measures and a shift towards higher-value healthcare products. CFO Micah Young noted that these actions resulted in a 750 basis point annual increase.
• Sales force restructuring: CEO Katie Szyman outlined a transition from product-based to regionally-focused sales teams. This shift is intended to leverage the full product portfolio and increase market penetration for advanced monitoring categories such as capnography and hemodynamics.
• Product innovation pipeline: Szyman highlighted next-generation patient monitors with AI-based algorithms as a key area of investment. These upcoming launches aim to expand Masimo’s presence in acute and post-acute care settings.
• Tariff mitigation planning: Management discussed detailed scenario planning to address new U.S. and China tariffs. Young explained that supply chain adjustments and sourcing changes are under evaluation, with mitigation steps expected to be phased in as regulatory clarity improves.

Drivers of Future Performance

Masimo’s forward-looking performance will depend on its ability to offset tariff pressures, execute its healthcare strategy, and maintain commercial momentum while investing in innovation.

• Tariff cost management: Management is actively scenario-planning to mitigate the impact of recently imposed tariffs, including supply chain shifts and potential pricing adjustments, with the goal of reducing margin pressure through 2025.
• Healthcare business refocus: The sale of the consumer audio division will free up resources to accelerate investments in patient monitoring technologies, AI-driven products, and sales force expansion—all positioned as growth catalysts for the core business.
• Operational investments and risks: Increased spending on commercial excellence and R&D, coupled with macroeconomic uncertainties such as labor costs and regulatory shifts, may create short-term margin volatility even as management expects long-term leverage.

Top Analyst Questions

• Frederick Wise (Stifel): Asked about the revenue and margin impact of a large contract and how underlying growth trends will normalize next quarter. Management explained the timing effect and stated that underlying demand remains strong, with seasonality expected to drive Q2 results.
• Vik Chopra (Wells Fargo): Queried whether tariffs will affect long-term margin goals and sought clarification on use of proceeds from the Sound United sale. CFO Micah Young confirmed ongoing margin expansion is expected and that share repurchases are prioritized over debt repayment.
• Jason Bednar (Piper Sandler): Requested insight into OEM partner signals on hospital spending and the rationale for confidence in guidance despite a recent cybersecurity incident. Management cited recurring revenue strength and robust protocols for addressing the incident.
• Mike Matson (Needham): Probed the strategy for hemodynamic monitoring and whether share repurchases will take precedence over debt repayment. CEO Szyman described the plan to integrate hemodynamics into next-gen monitors and focus on mid-to-low acuity hospital segments.
• Matt Taylor (Jefferies): Sought details on the margin expansion potential and the cadence of tariff impacts throughout the year. Management highlighted ongoing investments and explained that tariff effects will be weighted toward the fourth quarter.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the progress of Masimo’s sales force restructuring and its effect on new product adoption, (2) execution of supply chain and sourcing adjustments in response to tariffs, and (3) the pace and success of innovation in AI-based patient monitoring. Updates on the Sound United sale closing and deployment of proceeds will also be key markers for fundamental performance.

Masimo currently trades at a forward P/E ratio of 28.7×. At this valuation, is it a buy or sell post earnings? See for yourself in our free research report.

Stocks That Trumped Tariffs in 2018

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.